Responses
Clinical/translational cancer immunotherapy
Original research
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
Compose a Response to This Article
Other responses
No responses have been published for this article.